Series A · Biotech · Vilnius, Lithuania · Founded 2016 · 51–100 employees
Atrandi Biosciences transforms single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology, enabling scalable, true single-cell multiomics. The company isolates tens of thousands of single cells within discrete, permeable compartments, allowing bulk reactions while preserving single-cell resolution. Founded in 2016 as Droplet Genomics and rebranded in 2022, Atrandi has raised $25 million in Series A funding led by Lux Capital in February 2025, following a €4.5 million round in 2023. The company's platform powers over 200 research labs globally and has unlocked applications in high-throughput microbial and eukaryotic genomics.
No open roles listed right now.